NCT01002664View on ClinicalTrials.gov

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

PHASE3CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia
Interventions
DRUG

MCS-2

30 mg/day (two 15 mg capsules) Qd for 12 weeks

DRUG

Placebo

2 soft-gel placebo capsules Qd for 12 weeks

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Health Ever Bio-Tech Co., Ltd.

INDUSTRY